Why Is Skye Bioscience, Inc. (NASDAQ:SKYE) Climbing 15.93% in Pre-Market Trade on Tuesday?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Is Skye Bioscience, Inc. (NASDAQ:SKYE) Climbing 15.93% in Pre-Market Trade on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Skye Bioscience, Inc. (NASDAQ:SKYE) was indicated at USD 0.7999 before the US open on Tuesday, November 10, 2026, a 15.93% advance on a calculated prior close of USD 0.69, or roughly USD 0.11 a share.
An October 26, 2026 snapshot recorded a prior close of USD 1.54 and a 52-week range of USD 1.50 to USD 13.28, with 4.43 million shares, so the price now sits beneath that range.
The Phase 2a CBeyond combination arm delivered additional weight loss of 2.95 points, reaching 13.2% against 10.25% for semaglutide alone, with p equal to 0.0372.
Neither a company release nor a filing dated November 9 or November 10, 2026 was identified, so the move has no confirmed catalyst behind it.

Pre-Market Move in Skye Bioscience (15.93%)

Skye Bioscience was quoted at USD 0.7999 pre-market on Tuesday, November 10, 2026, 15.93% above a calculated prior close of USD 0.69 from Monday, November 9. That prior close sits roughly 55% under the USD 1.54 level in the October 26 snapshot, a calculation, and the present quote is 46.6% below the USD 1.50 52-week low, also calculated. The same snapshot showed 4.43 million shares and a market cap of USD 6.95 million, down 84.3% over twelve months. Applying USD 0.7999 to that count gives about USD 3.5 million, though the count may have moved since and is unverified.

Reasons Behind the Move

No catalyst surfaced in published coverage for November 9 or November 10, 2026. The latest items on its investor page were a transaction agreement with Redx Pharma dated August 14, 2026, which carried USD 125 million in financings, and a May 20, 2026 choice to open Cohort 2 following encouraging early safety results. Management has stated that present Capital will fund operations into 2027. The CBeyond monotherapy arm failed its primary weight-loss goal in October 2025, whereas the semaglutide pairing reached p of 0.0372, and a 26-week extension aims for 52 weeks of data. Clinical-stage biotechs tend to swing on trial updates, financing announcements, listing notices, reverse splits or sector moves in obesity medicines, and sub-USD 1 prices can draw momentum traders.

Valuation, Trading Depth and Risk

With a Market Value of only a few million dollars, cash might exceed Equity value, yet no current cash balance has been verified, so no ratio appears here. A published snapshot carried an average analyst target of USD 68.00 from four analysts, which looks out of step with the price and so is not relied upon. Volume in the October 26 snapshot was 18,794 shares. Under general Nasdaq rules, a share price below USD 1.00 can prompt a minimum bid deficiency notice after 30 consecutive Business days. Pre-market volumes are light, spreads may be wide, dilution risk is high for nano-cap biotechs, and the quote could reverse at the 9:30 a.m. ET open. Nothing in this points to the rise continuing.

Where Things Stand

Skye Bioscience, Inc. (NASDAQ:SKYE) is up 15.93% pre-market at USD 0.7999 on Tuesday, November 10, 2026, with no confirmed catalyst. The shares trade well below their USD 13.28 52-week high and under the USD 1.50 low, so this is a bounce from a deeply depressed level. Trial progress, financing terms and any exchange notice are the items to track, and for Australian investors holding the stock, the 9:30 a.m. ET open will put the quote to the test.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.